Suven Pharmaceuticals on Saturday posted a 31 per cent increase in its consolidated net profit at Rs 97 crore for the second quarter ended September 30.
The company had reported a net profit of Rs 74 crore in the July-September period of the previous fiscal.
Revenue from operations rose to Rs 301 crore for the quarter under review, as against Rs 237 crore in the year-ago period, Suven Pharmaceuticals said in a regulatory filing.
The COVID-19 pandemic continues to impact the business and research operations in India and our wholly-owned subsidiary, Suven pharma Inc USA, it noted.
"Apart from the above, the shortage or non-availability of vessels leading to delay in shipments, increase in the transportation and distribution costs and timely non-availability of materials with an increase in materials cost are impacting our operations and profitability," it added.
The Hyderabad-based company primarily operates in the contract development and manufacturing operations (CDMO) segment.
Meanwhile, grug firm Divi's Laboratories on Saturday reported a 16.71 per cent jump in its consolidated net profit to Rs 606.46 crore for the quarter ended September 30, mainly on account of robust sales.
The company had posted a net profit of Rs 519.59 crore for the corresponding period of the previous fiscal, Divi's Laboratories said in a filing to the BSE.
Its consolidated total income during July-September 2021 stood at Rs 2,006.62 crore. It was Rs 1,762.94 crore in the year-ago period, it added.
The group has not experienced any significant impact on its operations, supply chain and recoverability of carrying amounts of financial and non-financial assets due to the COVID 19 pandemic, Divi's Labs said.
(With PTI Inputs)
